Neon Therapeutics is based in Cambridge, MA
One of the much anticipated cancer immunotherapy presentations at the 2017 JP Morgan Healthcare conference was by Neon Therapeutics CEO Hugh O’Dowd.
As readers know we’re riding the Immuno-Oncology wave on Biotech Strategy Blog, and one of the exciting new topics to emerge is whether we can target neoantigens to create personalized immunotherapy.
Our mini-series last year on neonatigens received a lot of attention. It included a primer and three interviews. We were very much of the opinion that Neon Therapeutics is a company to watch out for.
In case you missed them, here are the links:
I highly recommending reading these articles as background on the science and new product development as a prelude to the latest commercialisation update we will cover in today’s post.
What did we learn from the 2017 JP Morgan presentation of the Neon Therapeutics corporate strategy?
If you didn’t make it to the presentation at JPM17 in San Francisco (it wasn’t webcast), you may be interested in this post. This is the latest update in our on-going series on neoantigens and why they matter in cancer immunotherapy.
Subscribers can login more or you can gain access via the blue box below…
As we continue our journey exploring neoantigens in the context of novel cancer research in Part 3 of our latest mini-series, today we focus on the commercialisation side of the business through an interview with a leading investor, Dr Cary Pfeffer, who is a partner in Third Rock Ventures, as well as being ad interim CEO of Neon Therapeutics. We’ve written about other Third Rock companies in the past; Agios, Foundation Medicine and bluebird bio come to mind, for example.
How does an exciting early product in development move from academia to industry? There are many ways to do this, so here is the story through the eyes of one young company with strong academic connections, as a way to illustrate what can be done. It isn’t the only way, by any means.
To be sure, there are other competitor companies in the neoantigen space – Gritstone and Moderna come to mind as examples – we will cover companies in the broader landscape in a future post. There is also an incredible amount of promising research going on in academia right now, which may lead to more companies or products being licensed and developed.
To learn more about what Cary Pfeffer had to say on Neon Therapeutics and neoantigens, subscribers can log-in or you can sign up in the blue box below:
This week we’re focusing on neoantigens, what role they have to play in cancer immunotherapy and novel approaches that identify and use them as a therapeutic modality.
When you look at the cancer immunotherapy landscape it’s like looking at a stained glass window – it’s not only about the light but seeing the patterns and way the glass is aesthetically arranged in order to make it effective.
Today’s post, the second in a mini-series of three, features an interview with a thought leader doing pioneering work at the forefront of how neoantigen based vaccines can be used to target solid tumors.
The field of vaccine based cancer immunotherapy research is attracting renewed interest from VCs, angel investors and academics because of it’s potential to be used in combination with other immunotherapies.
If you’d like to learn why, then you can purchase access below. Subscribers can login to read more.
National Harbor, MD. Today was a busy day with the ASH abstracts coming out this morning, and some ground-breaking data that demanded an immediate #ASH15 preview post.
At the same time we’re here at SITC, and keeping an eye on the AACR-NCI-EORTC Molecular Targets meeting – it’s like three buses come at once!
So what happened at SITC today? In this post we’ve put a quick summary of some of the presentations we heard on Day 2 that stood out. Sometimes what’s most important is what people don’t say.
Subscribers can login to read more or you can sign up in the box below.